Brezivaptan[1] (developmental code names ANC-501, THY-1773, TS-121) is an orally active, selective vasopressin V1B receptor antagonist which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder.

[2][3][4] As of November 2022, it is in phase II clinical trials for this indication.

[2][3][5]

This hormonal preparation article is a stub.

You can help Wikipedia by expanding it.